Dana-Farber/Harvard Cancer Center ETCTN collaboration (UM1)
Official title: Extension of the Dana Farber Harvard Cancer Center Consortium for the ETCTN
Funded at Dana-Farber Cancer Inst · NIH-11501600 · Data updated 2026-11-12
A large cancer research collaboration at Dana-Farber and partner Boston hospitals works to advance experimental cancer therapies and biomarker development.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | March 13, 2014 |
| Project end | February 28, 2027 |
| Funding year | 2026 |
| Award (this year) | $2,272,446 |
| NIH project number | 3UM1CA186709-09S2 |
| Project ID | NIH-11501600 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with advanced cancers who could benefit from EE/ETCTN trial opportunities, biomarker-guided therapies, or early-phase studies.
✕Less likely to help
Patients without eligible biomarkers or those not enrolled in ETCTN trials may not directly benefit.
What this research studies
This grant supports a leading cancer institute network in identifying and advancing new treatments for cancer patients, using translational science, biomarker work, and early-phase clinical trials. It involves a collaborative, multi-institution team that develops and tests targeted therapies, immunotherapies, and DNA repair–related approaches. The program emphasizes data-intensive methods, including liquid biopsies, computational biology, and model systems to move promising treatments toward patients. It also provides mentorship and regulatory oversight to support early-career researchers in translational oncology.
Why it matters
Potential benefit: If successful, patients with advanced cancers may gain access to innovative therapies and more precise treatment strategies.
How similar studies have gone: Previous ETCTN efforts have led to several trials and biomarker-driven approaches, illustrating potential for translational impact.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Shapiro, Geoffrey I. — Dana-Farber Cancer Inst
- Study coordinator: Shapiro, Geoffrey I.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.